French Dx developer bioMérieux advanced in Q2, thanks to emerging markets

French diagnostics developer bioMérieux said its 2013 second quarter generated solid growth, thanks to solid expansion in emerging markets like China, India and Brazil. Keeping currency fluctuations in mind, the company said it booked €395 million ($515.4 million) in sales during the quarter, a 4% rise compared to last year. For the first half of the year, that sales number hit €754 million ($986.5 million), a 2% increase versus the same period in 2012. Item

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.